Nuvalent (NUVL) Projected to Post Earnings on Thursday

Key Points

• Q1 2026 results due before the market opens on May 7: Analysts expect Nuvalent to report EPS of $(1.35) and revenue of $0.486 million, with a conference call scheduled for May 8 at 9:30 AM ET.
• Significant insider selling amid heavy institutional ownership: Insiders sold 44,523 shares worth about $4.64 million in the last quarter (including sales by the CFO and CEO), while corporate insiders own 10.20% and institutional investors own 97.26% of the stock.
• Stock and analyst backdrop: NUVL opened at $99.10 (52-week range $63.56–$113.01) with a $7.79 billion market cap, and Wall Street consensus is a "Moderate Buy" with an average target price of $137.25 (16 buys, 1 sell).

Nuvalent (NASDAQ:NUVL - Get Free Report) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Nuvalent to post earnings of ($1.35) per share and revenue of $0.4860 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:30 AM ET.

Nuvalent Stock Performance

Shares of NUVL stock opened at $99.10 on Thursday. Nuvalent has a 52-week low of $63.56 and a 52-week high of $113.01. The stock has a market cap of $7.79 billion, a price-to-earnings ratio of -16.94 and a beta of 1.31. The firm has a fifty day moving average of $102.02 and a 200-day moving average of $101.90.

Insider Buying and Selling

In related news, CFO Alexandra Balcom sold 11,430 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total transaction of $1,202,550.30. Following the completion of the sale, the chief financial officer owned 85,533 shares in the company, valued at $8,998,926.93. This trade represents a 11.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $103.77, for a total transaction of $3,113,100.00. Following the sale, the chief executive officer directly owned 324,879 shares in the company, valued at approximately $33,712,693.83. This represents a 8.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 44,523 shares of company stock worth $4,638,807 in the last quarter. 10.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds have recently added to or reduced their stakes in NUVL. AQR Capital Management LLC grew its holdings in Nuvalent by 64.8% during the 1st quarter. AQR Capital Management LLC now owns 9,874 shares of the company's stock worth $700,000 after acquiring an additional 3,881 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Nuvalent by 54.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company's stock worth $32,171,000 after acquiring an additional 159,873 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Nuvalent by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company's stock worth $10,634,000 after acquiring an additional 12,123 shares during the last quarter. Intech Investment Management LLC grew its holdings in Nuvalent by 28.7% during the 1st quarter. Intech Investment Management LLC now owns 19,262 shares of the company's stock worth $1,366,000 after acquiring an additional 4,293 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in Nuvalent during the 2nd quarter worth about $412,000. Institutional investors own 97.26% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NUVL shares. Wedbush reaffirmed an "outperform" rating and issued a $125.00 target price on shares of Nuvalent in a report on Wednesday, April 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvalent in a research report on Tuesday, April 21st. HC Wainwright reiterated a "buy" rating and set a $155.00 target price on shares of Nuvalent in a research report on Tuesday, April 21st. Wells Fargo & Company assumed coverage on shares of Nuvalent in a research report on Monday, March 30th. They set an "overweight" rating and a $116.00 target price for the company. Finally, Cantor Fitzgerald increased their target price on shares of Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Friday, February 27th. Sixteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Nuvalent currently has a consensus rating of "Moderate Buy" and an average target price of $137.25.

Nuvalent Company Profile

Nuvalent, Inc NASDAQ: NUVL is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.